Liquid Biopsy Cell‑Free PAN RAS (KRAS, NRAS) Mutation Panel in UAE – 3600 AED – DNA Labs UAE

Executive Summary & Core Metrics

Diagnostic Sensitivity: 99.9% via ISO 9001:2015 validated Droplet Digital PCR (ddPCR) methodology.
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection – available daily from 8 AM to 11 PM.
Clinical Guidance: Post‑test telephonic consultation with a specialist to interpret results in the context of your treatment plan.
Insurance Verification: Direct coverage check via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The Liquid Biopsy Cell‑Free PAN RAS (KRAS, NRAS) Mutation Panel detects tumor‑derived DNA mutations in peripheral blood using ultra‑sensitive Droplet Digital PCR (ddPCR), providing a non‑invasive alternative to tissue biopsy for guiding targeted therapy in oncology. This test identifies actionable genetic variants in KRAS and NRAS genes, critical for personalised treatment of colorectal, lung, and pancreatic cancers. Results enable oncologists to determine which patients are likely to benefit from anti‑EGFR therapies such as cetuximab and panitumumab, while sparing those with RAS mutations from ineffective treatments and unnecessary toxicity.

Feature	Our Test – ddPCR Liquid Biopsy	Closest Alternative – Tissue NGS
Method	Droplet Digital PCR (ddPCR) – single‑molecule sensitivity	Next‑Generation Sequencing (NGS) on tissue biopsy
Precision	>99.9% sensitivity; detects 0.01% mutant allele fraction	~95% sensitivity; dependent on tumour content
Specimen	Peripheral Blood – minimally invasive	Invasive biopsy (needle or surgical)
Turnaround Time	5–7 days	10–14 days
Cost	3,600 AED	4,500–6,000 AED (approximate)

Physician Insight & Safety Protocols

“As a specialist in diagnostic radiology closely involved in oncologic care, I recognise that waiting for genetic test results can be emotionally challenging. Clinical correlation is essential; a positive RAS mutation indicates lack of benefit from anti‑EGFR therapies, guiding alternative treatment strategies. Please discuss your specific case with your treating physician before making any treatment decisions.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011

Clinical Advisory – Medication Safety

⚠️ Important Pre‑Test Guidance

Do not discontinue, pause, or alter any prescribed medication without explicit instruction from your treating physician. The liquid biopsy result is one component of a comprehensive clinical assessment and should never be used as a standalone basis for treatment changes.

Exclusion Criteria & Emergency Red Flags

⚠️ When Immediate Medical Attention Is Required

Exclusion Criteria: This test is not suitable for minors without guardian consent as per Federal Decree‑Law No. 4 of 2016 on Medical Liability. Individuals undergoing active chemotherapy, radiation therapy, or immunotherapy should consult their oncologist prior to sample collection. Pregnancy and acute surgical cases require prior physician clearance.
Emergency Red Flags: If you experience severe abdominal pain, difficulty breathing, uncontrolled bleeding, or signs of anaphylaxis after blood draw, visit the nearest emergency department immediately. For urgent concerns, call 998 or proceed to the nearest hospital emergency room.

Patient FAQ & Clinical Guidance

1. What is a liquid biopsy for PAN RAS mutations?

A liquid biopsy for PAN RAS (KRAS, NRAS) uses a simple blood draw to detect tumor DNA mutations non‑invasively. This ddPCR test identifies circulating tumor DNA with ultra‑high sensitivity, enabling oncologists to select targeted therapies such as cetuximab or panitumumab only in RAS wild‑type patients, thereby avoiding ineffective treatments and unnecessary side effects. Because it requires only a peripheral blood sample, it is safe, repeatable, and suitable for patients who cannot undergo invasive tissue biopsy.

2. How accurate is ddPCR for RAS mutation detection compared to tissue biopsy?

ddPCR provides over 99% sensitivity for detecting low‑level RAS mutations in plasma, equalling tissue biopsy results. Its exceptional analytical sensitivity allows detection of mutant alleles even when the tumour DNA fraction is extremely low, making it highly concordant with invasive tissue testing while being safer and repeatable. Clinical studies show a concordance rate exceeding 95% between plasma ddPCR and tissue NGS for RAS mutation detection in colorectal cancer.

3. Do I need a doctor’s prescription for this test?

Yes, a valid medical prescription from a licensed physician is required for this liquid biopsy. The test is intended for patients with a known or suspected diagnosis of colorectal, lung, or pancreatic cancer where RAS mutation status informs treatment selection. Individuals planning to travel abroad, or those preparing for surgery, may have specific documentation needs — please verify your situation with our support team via WhatsApp.

4. What happens after the test results are ready?

Your results will be delivered electronically and reviewed during a telephonic consultation with a specialist. The report includes qualitative detection of KRAS and NRAS mutations along with allele frequency where applicable. Your treating oncologist will integrate these findings with your clinical history, imaging, and pathology to determine the optimal treatment strategy. A negative RAS result (wild‑type) supports the use of anti‑EGFR therapies, while a positive result guides alternative approaches such as chemotherapy or clinical trials.

5. Can I schedule a home blood collection for this test?

Yes, because the specimen is peripheral blood, our VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection service is available daily from 8 AM to 11 PM. A DHA‑licensed phlebotomist will visit your residence or hotel, collect the sample under sterile conditions, and transport it to our laboratory via certified cold‑chain logistics. This service is available across all Emirates including Dubai, Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain.

UAE Regulatory & Data Privacy Adherence

Compliance Framework: This service fully adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) governing the collection, processing, and storage of personal health data, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields regulating digital health information systems. Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. The laboratory operates under DHA Facility License Number 1143 and is located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate branding: DNA Labs UAE. Quality management is certified under ISO 9001:2015. All home collections are performed by DHA‑licensed phlebotomists following validated cold‑chain protocols.

Clinical & Logistical Metadata

Test Name	Liquid Biopsy Cell‑Free PAN RAS (KRAS, NRAS) Mutation Panel
Price (AED)	3,600 AED
Turnaround Time	5–7 business days
Sample Type / Matrix	Peripheral Blood (plasma cell‑free DNA) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM – 11 PM
Methodology Used	Droplet Digital PCR (ddPCR) – single‑molecule sensitivity, 0.01% mutant allele fraction detection
ICD-10-CM Code	C80.1 (Malignant neoplasm without specification of site)
LOINC Code	94488-8 (KRAS gene mutation analysis in Plasma cell‑free DNA by Sequencing)
DHA Facility License & Laboratory Address	License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE